# CARINH, an Interferon-Induced LncRNA in Cancer and Inflammation

## TL;DR

CARINH is a long noncoding RNA involved in immune responses, inflammation, and cancer, with potential as a biomarker and therapeutic target.

## Contribution

This review highlights CARINH's dual role in immune regulation and cancer, focusing on its molecular mechanisms and therapeutic potential.

## Key findings

- CARINH is conserved across species and plays a key role in antiviral defense.
- Dysregulation of CARINH is linked to autoimmune disorders and cancer progression.
- CARINH modulates interferon responses and influences tumor suppression pathways.

## Abstract

CARINH is an intriguing long noncoding RNA whose unique regulatory functions intersect the seemingly distinct processes of innate immunity and cancer development. Notably, CARINH is conserved across species, offering powerful experimental models for uncovering its mechanistic roles and physiological functions across diverse biological contexts. Stimulated by interferons and viral infections, CARINH stands out as a key player in the body’s antiviral defense mechanisms. Additionally, its dysregulation has been implicated in autoimmune disorders such as psoriasis, asthma, and inflammatory bowel disease, underscoring its broader role in maintaining immune homeostasis. Furthermore, alterations in CARINH expression have been connected to cancer progression, highlighting its dual role in immune response and tumor suppression. In this review, we delve into CARINH’s pivotal function in modulating interferon responses and influencing cancer development, with a focus on the molecular pathways that regulate its expression and contribute to its diverse roles. Understanding these pathways is crucial for evaluating CARINH’s significance as a biomarker and therapeutic target, potentially leading to groundbreaking advancements in medical research and treatment strategies.